Brokers Issue Forecasts for CADL Q4 Earnings

Candel Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Brookline Capital Markets slightly improved its Q4 2026 EPS forecast for Candel Therapeutics, to a loss of $0.31 per share from $0.32; its full-year consensus estimate is a loss of $1.29 per share.
  • Candel reported a quarterly loss of $0.28 per share, better than the $0.34 loss analysts expected.
  • Analyst views are mixed: MarketBeat’s consensus is “Moderate Buy,” but Candel’s delayed aglatimagene BLA submission to mid-2027 has weighed on sentiment, alongside several reduced price targets.
  • MarketBeat previews the top five stocks to own by December 1st.

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities researchers at Brookline Capital Markets upped their Q4 2026 earnings per share estimates for shares of Candel Therapeutics in a research note issued to investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.32). The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.29) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics' Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.42) EPS.

CADL has been the topic of several other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Bank of America upgraded Candel Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $12.00 to $18.00 in a report on Monday, September 21st. UBS Group reaffirmed a "buy" rating on shares of Candel Therapeutics in a research report on Monday, August 17th. Jefferies Financial Group assumed coverage on Candel Therapeutics in a report on Thursday, October 22nd. They set a "buy" rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group dropped their target price on Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating on the stock in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.29.

Read Our Latest Analysis on Candel Therapeutics

Candel Therapeutics Stock Down 6.3%

Shares of CADL stock opened at $5.81 on Tuesday. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00. The firm's fifty day moving average price is $9.61 and its two-hundred day moving average price is $8.39. The firm has a market capitalization of $444.58 million, a P/E ratio of -3.93 and a beta of -0.27.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at about $51,181,000. Goldman Sachs Group Inc. grew its holdings in Candel Therapeutics by 4.1% during the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company's stock worth $3,316,000 after purchasing an additional 12,385 shares during the period. Bank of America Corp DE bought a new position in Candel Therapeutics during the second quarter worth about $2,873,000. Wellington Management Group LLP bought a new position in Candel Therapeutics during the second quarter worth about $2,119,000. Finally, Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the second quarter worth approximately $1,975,000. Institutional investors own 13.93% of the company's stock.

Trending Headlines about Candel Therapeutics

Here are a few of the latest headlines about CADL:

  • Positive Sentiment: Citigroup lowered its price target from $26 to $20 but maintained a Buy rating, implying substantial upside from the cited share price. Citigroup rating
  • Negative Sentiment: Candel pushed the aglatimagene BLA submission to mid-2027. The delay followed earlier statements about filing timing and came after the company raised $80 million partly to prepare the application, prompting a sharp selloff and continued pressure on the shares. The Pharma Letter article
  • Negative Sentiment: HC Wainwright, Canaccord Genuity, and Stifel Nicolaus also reportedly reduced their price targets, reflecting a more cautious outlook following the filing delay. HC Wainwright price target report

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Candel Therapeutics Right Now?

Before you consider Candel Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.

While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines